PIXIE-DUST-TECHNOLOGIES
20.12.2023 04:01:34 CET | Business Wire | Press release
Pixie Dust Technologies, Inc., Shionogi & Co., Ltd, and Shionogi Healthcare Co., Ltd released “Memory” and “Tomorrow”, two audio experiences incorporating gamma wave technology1 designed to provide dementia patients with an additional tool that they can use to care for their cognitive function.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231219774481/en/
Gamma Wave Sound (Graphic: Business Wire)
It is estimated that every 3 seconds, someone develops dementia – a general term for a decline in mental ability severe enough to interfere with daily life. By 2050, more than 150 million people globally will live with dementia. Patients can preserve their quality of life and enhance overall wellness by engaging in activities that stimulate the brain.
Ongoing studies2345 demonstrate that repeated exposure to 40Hz gamma waves can promote brain function by reducing white matter atrophy and myelin loss, which contribute to Alzheimer’s disease progression. Data validated by Pixie Dust Technologies Inc. and Shionogi & Co., Ltd confirmed that gamma wave power and its entrainment increased when listening to amplitude-modulated 40Hz sounds, suggesting that such sounds can be clinically applied to dementia prevention as a non-invasive method.
The Dementia Care Project by Gamma Wave Sound is an initiative designed to help people care for their cognitive function through auditory stimulation. Turning gamma waves technology into a readily available audio experience presents new possibilities in providing cognitive stimulation for dementia.
Six major companies across industries in Japan have come together to form the alliance to boost dementia care as part of the Dementia Care Project by Gamma Wave Sound. These diverse companies share a common goal – to bring integrated daily care of cognitive function through its public touchpoints.
The number of participating companies continues to grow under the initiative, with gamma wave sound experience being brought to places where sound can be heard, such as the largest shopping malls and fitness gym’s exercising program, and local onsen resting spots in Japan.
Expanding to other countries as an international effort, Alii Palau Airlines, which provides direct flight service between Singapore and Palau, is playing both gamma wave audio tracks “Memory” and “Tomorrow”.
Furthermore, music artists who support the initiative have released the Gamma Wave Sound edit of their tracks, accelerating the efforts to deliver Gamma Wave Sound through entertainment.
The original soundtracks are available for download on YouTube (Memory (Gamma Wave Sound Edit) , Tomorrow (Gamma Wave Sound Edit)) , Spotify, Apple Music Podcast.
For more information, please visit our website at: https://www.project.gammawavesound.com/home-1
References
1 Patent filed in Japan; patented technology processes audio by performing 40Hz amplitude modulation on partial signals included in input audio.
2 Martorell, A. J., Paulson, A. L., Suk, H. J., Abdurrob, F., Drummond, G. T., Guan, W., ... & Tsai, L. H. (2019). Multi-sensory gamma stimulation ameliorates Alzheimer’s-associated pathology and improves cognition. Cell, 177(2), 256-271.
3 Cognito Therapeutics Presents New MRI Data Showing Non-Invasive Gamma Stimulation Therapy Reduces Brain Atrophy and Myelin Loss in Alzheimer’s Disease. (2023, June 17).
4 Business Wire: Cognito Therapeutics Announces First Patient Enrollment in US Pivotal Study HOPE
5-1 Business Wire: Cognito Therapeutics Announces Proprietary Gamma Sensory Stimulation for 6-Months Reduces White Matter Atrophy in Alzheimer’s Disease Patients
5-2 2023 Association for Research in Otolaryngology Midwinter Meeting Abstract Book, pp.443-444 (2023).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231219774481/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release
The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release
This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
